Immune cell reprogramming offers hope for stubborn arthritis and Sjogren's
NCT ID NCT07048197
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a personalized cell therapy (rapcabtagene autoleucel) in 27 adults with difficult-to-treat rheumatoid arthritis or severe Sjogren's disease. The treatment uses a patient's own immune cells, modified to target and calm the overactive immune system. The main goal is to check safety and how the cells behave in the body, with early signs of effectiveness also being explored.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RHEUMATOID ARTHRITIS (RA) AND SJÖGREN'S DISEASE (SJD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novartis Investigative Site
RECRUITINGBordeaux, 33076, France
-
Novartis Investigative Site
RECRUITINGBrest, 29200, France
-
Novartis Investigative Site
RECRUITINGLe Kremlin-Bicêtre, 94275, France
-
Novartis Investigative Site
RECRUITINGLille, 59037, France
-
Novartis Investigative Site
RECRUITINGFreiburg im Breisgau, Baden-Wurttemberg, 79106, Germany
-
Novartis Investigative Site
RECRUITINGGöttingen, Lower Saxony, 37075, Germany
-
Novartis Investigative Site
RECRUITINGCologne, North Rhine-Westphalia, 50937, Germany
-
Novartis Investigative Site
RECRUITINGBerlin, 13353, Germany
-
Novartis Investigative Site
RECRUITINGUlm, 89081, Germany
-
Novartis Investigative Site
RECRUITINGSingapore, 119074, Singapore
-
Novartis Investigative Site
RECRUITINGBarcelona, 08035, Spain
-
Novartis Investigative Site
RECRUITINGMadrid, 28034, Spain
More trials for these conditions
Other studies related to the condition(s) this trial covers.